Genetic testing study for plasma cell disorders
Part of Cancer clinical trials.
This study looks at how genetic changes affect the treatment and outcomes of plasma cell disorders, including MGUS, smoldering myeloma, multiple myeloma, and amyloidosis. Participants must have had genetic tests (FISH or NGS) and at least one year of follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a plasma cell disorder such as MGUS, smoldering myeloma, multiple myeloma, or amyloidosis.
- You are 18 years old or older.
- You have had a genetic test called FISH or NGS as part of your care.
- You have been followed for treatment for at least one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
This study is collecting blood samples from people with plasma cell disorders to help researchers learn more about these conditions. It may be a good fit if you haven't started treatment yet and are willing to donate samples.
This study creates a long-term database of patients with plasma cell disorders (such as multiple myeloma) to improve future care. You would be helping doctors learn more about these conditions by sharing your records over time.
This registry collects information from adults with certain plasma-cell conditions like MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis. It may help researchers learn more about these diseases and improve future care.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.